Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 10/2017

23.08.2017 | Original Article

The difference in medical costs between carbapenem-resistant Acinetobacter baumannii and non-resistant groups: a case study from a hospital in Zhejiang province, China

verfasst von: X. Zhen, Y. Chen, X. Hu, P. Dong, S. Gu, Y. Y. Sheng, H. Dong

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 10/2017

Einloggen, um Zugang zu erhalten

Abstract

This retrospective study aims to compare differences in the medical costs between inpatients infected/colonised with carbapenem-resistant (CRAB) and carbapenem-susceptible (CSAB) Acinetobacter baumannii in a hospital in Zhejiang province, China. Because the patient population was large, we randomly selected 60% of all inpatients with clinical specimens between 2013 and 2015. We classified the A. baumannii cases as CRAB or CSAB based on antibiotic susceptibility testing. Univariate and multivariate analyses were used to identify factors associated with the total medical cost (TMC). Those included in the study totalled 2980 inpatients, 71.3% of whom had CRAB infection/colonisation. Differences in the TMC between the CRAB and CSAB groups were lower by multivariate analyses than the differences obtained by univariate analyses. Carbapenem resistance was significantly associated with an approximately 1.5-fold increase in the TMC after accounting for confounding factors. Our study highlights the heavy financial burden imposed by A. baumannii and carbapenem resistance on the Chinese healthcare system.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Henig O, Weber G, Hoshen MB, Paul M, German L, Neuberger A et al (2015) Risk factors for and impact of carbapenem-resistant Acinetobacter baumannii colonization and infection: matched case–control study. Eur J Clin Microbiol 34:2063–2068CrossRef Henig O, Weber G, Hoshen MB, Paul M, German L, Neuberger A et al (2015) Risk factors for and impact of carbapenem-resistant Acinetobacter baumannii colonization and infection: matched case–control study. Eur J Clin Microbiol 34:2063–2068CrossRef
3.
Zurück zum Zitat Djordjevic ZM, Folic MM, Folic ND, Gajovic N, Gajovic O, Jankovic SM (2016) Risk factors for hospital infections caused by carbapanem-resistant Acinetobacter baumannii. J Infect Dev Ctries 10:1073–1080CrossRefPubMed Djordjevic ZM, Folic MM, Folic ND, Gajovic N, Gajovic O, Jankovic SM (2016) Risk factors for hospital infections caused by carbapanem-resistant Acinetobacter baumannii. J Infect Dev Ctries 10:1073–1080CrossRefPubMed
4.
Zurück zum Zitat Qureshi ZA, Hittle LE, O’Hara JA, Rivera JI, Syed A, Shields RK et al (2015) Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clin Infect Dis 60:1295–1303CrossRefPubMedPubMedCentral Qureshi ZA, Hittle LE, O’Hara JA, Rivera JI, Syed A, Shields RK et al (2015) Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clin Infect Dis 60:1295–1303CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Ozsurekci Y, Aykac K, Cengiz AB, Basaranoglu ST, Sancak B, Karahan S et al (2017) Bloodstream infections in children caused by carbapenem-resistant versus carbapenem-susceptible gram-negative microorganisms: risk factors and outcome. Diagn Microbiol Infect Dis 87:359–364CrossRefPubMed Ozsurekci Y, Aykac K, Cengiz AB, Basaranoglu ST, Sancak B, Karahan S et al (2017) Bloodstream infections in children caused by carbapenem-resistant versus carbapenem-susceptible gram-negative microorganisms: risk factors and outcome. Diagn Microbiol Infect Dis 87:359–364CrossRefPubMed
6.
Zurück zum Zitat Tal-Jasper R, Katz DE, Amrami N, Ravid D, Avivi D, Zaidenstein R et al (2016) Clinical and epidemiological significance of carbapenem resistance in Acinetobacter baumannii infections. Antimicrob Agents Chemother 60:3127–3131CrossRefPubMedPubMedCentral Tal-Jasper R, Katz DE, Amrami N, Ravid D, Avivi D, Zaidenstein R et al (2016) Clinical and epidemiological significance of carbapenem resistance in Acinetobacter baumannii infections. Antimicrob Agents Chemother 60:3127–3131CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Hu FP, Guo Y, Zhu DM, Wang F, Jiang XF, Xu YC et al (2016) Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005–2014. Clin Microbiol Infect 22:S9–S14CrossRefPubMed Hu FP, Guo Y, Zhu DM, Wang F, Jiang XF, Xu YC et al (2016) Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005–2014. Clin Microbiol Infect 22:S9–S14CrossRefPubMed
8.
Zurück zum Zitat Mezzatesta ML, D’Andrea MM, Migliavacca R, Giani T, Gona F, Nucleo E et al (2012) Epidemiological characterization and distribution of carbapenem-resistant Acinetobacter baumannii clinical isolates in Italy. Clin Microbiol Infect 18:160–166CrossRefPubMed Mezzatesta ML, D’Andrea MM, Migliavacca R, Giani T, Gona F, Nucleo E et al (2012) Epidemiological characterization and distribution of carbapenem-resistant Acinetobacter baumannii clinical isolates in Italy. Clin Microbiol Infect 18:160–166CrossRefPubMed
9.
Zurück zum Zitat Thatrimontrichai A, Techato C, Dissaneevate S, Janjindamai W, Maneenil G, Kritsaneepaiboon S et al (2016) Risk factors and outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia in the neonate: a case–case–control study. J Infect Chemother 22:444–449CrossRefPubMed Thatrimontrichai A, Techato C, Dissaneevate S, Janjindamai W, Maneenil G, Kritsaneepaiboon S et al (2016) Risk factors and outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia in the neonate: a case–case–control study. J Infect Chemother 22:444–449CrossRefPubMed
10.
Zurück zum Zitat Wang M (2015) Current status and trends of antimicrobial resistance in China. China Antimicrobial Resistance Surveillance System. Available online at: http://www.carss.cn/. Accessed 28 Oct 2016 Wang M (2015) Current status and trends of antimicrobial resistance in China. China Antimicrobial Resistance Surveillance System. Available online at: http://​www.​carss.​cn/​. Accessed 28 Oct 2016
11.
Zurück zum Zitat Lautenbach E, Synnestvedt M, Weiner MG, Bilker WB, Vo L, Schein J et al (2009) Epidemiology and impact of imipenem resistance in Acinetobacter baumannii. Infect Control Hosp Epidemiol 30:1186–1192CrossRefPubMed Lautenbach E, Synnestvedt M, Weiner MG, Bilker WB, Vo L, Schein J et al (2009) Epidemiology and impact of imipenem resistance in Acinetobacter baumannii. Infect Control Hosp Epidemiol 30:1186–1192CrossRefPubMed
14.
Zurück zum Zitat Chusri S, Silpapojakul K, McNeil E, Singkhamanan K, Chongsuvivatwong V (2015) Impact of antibiotic exposure on occurrence of nosocomial carbapenem-resistant Acinetobacter baumannii infection: a case control study. J Infect Chemother 21:90–95CrossRefPubMed Chusri S, Silpapojakul K, McNeil E, Singkhamanan K, Chongsuvivatwong V (2015) Impact of antibiotic exposure on occurrence of nosocomial carbapenem-resistant Acinetobacter baumannii infection: a case control study. J Infect Chemother 21:90–95CrossRefPubMed
16.
Zurück zum Zitat Lee NY, Lee HC, Ko NY, Chang CM, Shih HI, Wu CJ et al (2007) Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol 28:713–719CrossRefPubMed Lee NY, Lee HC, Ko NY, Chang CM, Shih HI, Wu CJ et al (2007) Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol 28:713–719CrossRefPubMed
17.
Zurück zum Zitat Lee H, Lee H (2016) Clinical and economic evaluation of multidrug-resistant Acinetobacter baumannii colonization in the intensive care unit. Infect Chemother 48:174–180CrossRefPubMedPubMedCentral Lee H, Lee H (2016) Clinical and economic evaluation of multidrug-resistant Acinetobacter baumannii colonization in the intensive care unit. Infect Chemother 48:174–180CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Yang L, Xiao YH, Nie Y, Zheng YD, Wang J, Yan Q et al (2010) Impact of misuse of antimicrobial therapies on inpatient costs. J Peking Univ (Health Sciences) 42:279–283 Yang L, Xiao YH, Nie Y, Zheng YD, Wang J, Yan Q et al (2010) Impact of misuse of antimicrobial therapies on inpatient costs. J Peking Univ (Health Sciences) 42:279–283
19.
Zurück zum Zitat Wu D, Cai J, Liu J (2011) Risk factors for the acquisition of nosocomial infection with carbapenem-resistant Klebsiella pneumoniae. South Med J 104:106–110CrossRefPubMed Wu D, Cai J, Liu J (2011) Risk factors for the acquisition of nosocomial infection with carbapenem-resistant Klebsiella pneumoniae. South Med J 104:106–110CrossRefPubMed
20.
Zurück zum Zitat Jiao Y, Qin Y, Liu J, Li Q, Dong Y, Shang Y et al (2015) Risk factors for carbapenem-resistant Klebsiella pneumoniae infection/colonization and predictors of mortality: a retrospective study. Pathog Glob Health 109:68–74CrossRefPubMedPubMedCentral Jiao Y, Qin Y, Liu J, Li Q, Dong Y, Shang Y et al (2015) Risk factors for carbapenem-resistant Klebsiella pneumoniae infection/colonization and predictors of mortality: a retrospective study. Pathog Glob Health 109:68–74CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Judd WR, Ratliff PD, Hickson RP, Stephens DM, Kennedy CA (2016) Clinical and economic impact of meropenem resistance in Pseudomonas aeruginosa-infected patients. Am J Infect Control 44:1275–1279CrossRefPubMed Judd WR, Ratliff PD, Hickson RP, Stephens DM, Kennedy CA (2016) Clinical and economic impact of meropenem resistance in Pseudomonas aeruginosa-infected patients. Am J Infect Control 44:1275–1279CrossRefPubMed
22.
23.
Zurück zum Zitat Burns AS, Santos A, Cheng CL, Chan E, Fallah N, Atkins D et al (2017) Understanding length of stay after spinal cord injury: Insights and limitations from the access to care and timing project. J Neurotrauma Burns AS, Santos A, Cheng CL, Chan E, Fallah N, Atkins D et al (2017) Understanding length of stay after spinal cord injury: Insights and limitations from the access to care and timing project. J Neurotrauma
24.
Zurück zum Zitat Stone PW, Braccia D, Larson E (2005) Systematic review of economic analyses of health care-associated infections. Am J Infect Control 33:501–509CrossRefPubMed Stone PW, Braccia D, Larson E (2005) Systematic review of economic analyses of health care-associated infections. Am J Infect Control 33:501–509CrossRefPubMed
25.
Zurück zum Zitat Yan T, Li Z, Yu A (2016) Analysis on four kinds of common diseases hospital costs between medical insurance and self-financed patients in a Xinjiang tertiary level hospital. Chin Med Rec 17:67–69 Yan T, Li Z, Yu A (2016) Analysis on four kinds of common diseases hospital costs between medical insurance and self-financed patients in a Xinjiang tertiary level hospital. Chin Med Rec 17:67–69
26.
Zurück zum Zitat Li Z, Wang L, Pan W (2016) Cause analysis for the unreasonable expenses of hospitalization insurance expenses. Hospital Administration Journal of Chinese People’s Liberation Army 23:75–77 Li Z, Wang L, Pan W (2016) Cause analysis for the unreasonable expenses of hospitalization insurance expenses. Hospital Administration Journal of Chinese People’s Liberation Army 23:75–77
27.
Zurück zum Zitat Wang MH, Cao Q, Lu GC (2009) Contrast of hospitalization expense and analysis of its affecting factors between the patients with medical insurance and without. Chin Health Econ 28:35–37CrossRef Wang MH, Cao Q, Lu GC (2009) Contrast of hospitalization expense and analysis of its affecting factors between the patients with medical insurance and without. Chin Health Econ 28:35–37CrossRef
28.
Zurück zum Zitat Sheng WH, Liao CH, Lauderdale TL, Ko WC, Chen YS, Liu JW et al (2010) A multicenter study of risk factors and outcome of hospitalized patients with infections due to carbapenem-resistant Acinetobacter baumannii. Int J Infect Dis 14:e764–e769CrossRefPubMed Sheng WH, Liao CH, Lauderdale TL, Ko WC, Chen YS, Liu JW et al (2010) A multicenter study of risk factors and outcome of hospitalized patients with infections due to carbapenem-resistant Acinetobacter baumannii. Int J Infect Dis 14:e764–e769CrossRefPubMed
Metadaten
Titel
The difference in medical costs between carbapenem-resistant Acinetobacter baumannii and non-resistant groups: a case study from a hospital in Zhejiang province, China
verfasst von
X. Zhen
Y. Chen
X. Hu
P. Dong
S. Gu
Y. Y. Sheng
H. Dong
Publikationsdatum
23.08.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 10/2017
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-017-3088-3

Weitere Artikel der Ausgabe 10/2017

European Journal of Clinical Microbiology & Infectious Diseases 10/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.